API
< Back to all clusters
[BUSINESS] · Spain, Egypt, United States · 11 sources

started · updated

Grifols faces high debt levels despite business growth

Grifols, the Catalan pharmaceutical company specializing in blood plasma collection and treatment, is navigating significant financial challenges despite recent improvements in financial indicators and governance changes. The company's market value has dropped from a pre-pandemic peak of 21,000 million euros to just over 4,000 million euros.

A primary concern is the company's substantial debt, which previously exceeded 9,400 million euros and currently remains above 7,500 million euros. This level of debt is reported to be roughly double what would be considered normal for similar enterprises.

The company's financial difficulties were exacerbated by the COVID-19 pandemic, which disrupted plasma donation chains and increased the cost of raw materials. Additionally, heavy investment in acquisitions to drive growth contributed to the debt load. To diversify its supply chain and reduce dependence on the United States, Grifols is pursuing a strategic project in Egypt to collect and process plasma locally.

Entities

Egypt · GVC Gaesco · Grifols · Jaume Puig · United States

Claims

What the coverage asserts, and how many sources carry each claim.